$500 million bet on BNB! Pharmaceutical company Liminatus Pharma establishes "US BNB Strategy" subsidiary: optimistic about BNB ecosystem returns.

US pharmaceutical company Liminatus Pharma announced that it will establish a “US BNB Strategy” subsidiary, expecting to utilize up to $500 million for long-term investment and holding of BNB. (Background: BNB breaks through $860 to reach new highs! Market capitalization surpasses MicroStrategy, Nike, and SoftBank, with Nano Labs increasing the position by 8,000 BNB) (Background supplement: When BNB enters the mainstream digital asset: what opportunities does the era bring from Nasdaq to sovereign reserves?) The BNB reserve company welcomes a new member! Originally focused on cancer immunotherapy, US pharmaceutical company Liminatus Pharma announced that it will establish a “US BNB Strategy” subsidiary, expecting to utilize up to $500 million for long-term investment and holding of BNB. Why is traditional biotech betting on BNB? According to the press release, Liminatus Pharma CEO Chris Kim pointed out three core reasons explaining why they chose to stake BNB: First, the technology of BNB Chain and its global user base have formed a network effect; second, Binance’s Launchpool, staking, and other mechanisms provide stable and continuous returns; third, the overall BNB ecosystem establishes a clear value bridge between decentralized finance (DeFi) and real-world applications. He stated in a conference call: “This is not short-term speculation. We believe in the long-term growth potential of BNB, which can enhance the company’s capital efficiency and allow shareholders to gain additional returns outside our drug development business.” Risk management behind the $500 million It’s worth noting that $500 million is not a small amount. Therefore, Liminatus Pharma stated that it will use Ceffu’s institutional-grade custody services and adopt a phased investment approach to mitigate the risks posed by market fluctuations and compliance issues. At the same time, in its internal planning, Liminatus Pharma has set up three mechanisms: segmented fund release, dynamic position limits tied to cash flow, and quarterly reviews by the board of directors. LIMN rises 4.3% before market According to Google Finance data, possibly influenced by this news, Liminatus Pharma’s stock slightly rose before the US market opened, with an increase of about 4.3%, and the pre-market stock price was reported at $9.09, with a market capitalization of about $227 million. Related reports BNB breaks through $800 to create a historical new high, entering a new price discovery phase after seven months US pharmaceutical company Windtree Therapeutics plans to establish a “$200 million BNB reserve”; CZ says: More BNB MicroStrategies are coming Wall Street reports a $100 million investment to build a “BNB Reserve Company” for listing, CZ reveals: more than one is doing it <“$500 million stake in BNB! Pharmaceutical company Liminatus Pharma establishes a ‘US BNB Strategy’ subsidiary: optimistic about BNB ecological returns”> This article was first published on BlockTempo, the most influential blockchain news media.